Ideaya Biosciences Inc (Ideaya) is a precision medicine company that develops oncology therapeutics. The company’s product pipeline includes darovasertib (IDE196), a protein kinase C (PKC) inhibitor that targets cancers with GNAQ and GNA11 mutations. It develops small molecule inhibitors based on synthetic lethality against known and novel targets. Ideaya also provides solutions for treating tumors with genetic mutations in homologous recombination deficiency(HRD) and high microsatellite instability (MSI). The company collaborates with Novartis Institute for Biomedical Research, Pfizer Inc, Boston Children’s Hospital, Cancer Research UK, and other academic and research institutes for cancer biology, immunology, and small molecule drug discovery. Ideaya is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
7000 Shoreline Ct Ste 350, South San Francisco, California, 94080-7604
Website
www.ideayabio.com
Telephone
1 650 4436209
No of Employees
124
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IDYA (NASD)
Revenue (2022)
$23.4M
-54.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-92.6%
(2022 vs 2021)
Market Cap*
$2.9B
Net Profit Margin (2022)
XYZ
-319.4%
(2022 vs 2021)
* As of and is in US$
Ideaya Biosciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipelines: |
| Darovasertib (IDE196) |
| PKC Inhibitor |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Ideaya Biosciences Inc | MEI Pharma Inc | Alaunos Therapeutics Inc | ProLynx LLC |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | South San Francisco | San Diego | Houston | San Francisco |
| State/Province | California | California | Texas | California |
| No. of Employees | 124 | 46 | 1 | 10 |
| Entity Type | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Timothy M. Shannon | Chairman | Executive Board | 2016 | 64 |
| Yujiro S. Hata | Director; President; Chief Executive Officer | Executive Board | 2015 | 48 |
| Paul A. Stone | Chief Financial Officer | Senior Management | 2019 | 59 |
| Paul A. Barsanti | Chief Technology Officer | Senior Management | - | - |
| Jason S. Throne | Secretary; Chief Legal Officer | Senior Management | 2023 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer